Ultragenyx Pharmaceutical Inc (LTS:0LIF)
$ 51.134 0.686 (1.35%) Market Cap: 4.70 Bil Enterprise Value: 3.98 Bil PE Ratio: 0 PB Ratio: 10.88 GF Score: 72/100

Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 07:50PM GMT
Release Date Price: $139.31
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm senior large-cap biotech analyst. And it's my pleasure to introduce our next company, Ultragenyx Pharmaceutical and CEO, Emil Kakkis.

Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the little blue button in your conference portal. So with that, Emil, thank you for being here today, and let me turn things over to you.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks, Cory. Thanks for having me today, and welcome, everyone. Ultragenyx, if you're on the first slide, I'd move on to your second slide is the legal warning. And let's move on to the next. The companies now after 10 years, been building really an exceptional rare disease company from the standpoint of building a commercial enterprise with the Crysvita, Dojolvi launch

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot